Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 d...

Full description

Bibliographic Details
Main Authors: Olson, Calla M, Jiang, Baishan, Erb, Michael A, Liang, Yanke, Doctor, Zainab M, Zhang, Zinan, Zhang, Tinghu, Kwiatkowski, Nicholas, Boukhali, Myriam, Green, Jennifer L, Haas, Wilhelm, Nomanbhoy, Tyzoon, Fischer, Eric S, Bradner, James E, Winter, Georg E, Gray, Nathanael S, Young, Richard A.
Other Authors: Massachusetts Institute of Technology. Department of Biology
Format: Article
Published: Nature Publishing Group 2018
Online Access:http://hdl.handle.net/1721.1/117495
https://orcid.org/0000-0001-8855-8647

Internet

http://hdl.handle.net/1721.1/117495
https://orcid.org/0000-0001-8855-8647

Similar Items